Pricing
Pharma Pricing Probe Puts Spotlight On Drug Compounding
The continuing campaign to ratchet down prescription drug prices has generated considerable talk about how compounders could provide less costly, alternative therapies. Jill Wechsler reports
...Read more |
 |
Event Round-Up
TEDMED 2015
Three days at TEDMED has convinced Bill Drummy that a dramatic shift in the definition of what's possible is not only re-energizing, it can also help you approach your biggest problems in ways you would have never otherwise considered
...Read more |
 |
Advertising
Last Call To Enter 4A’s 2016 Partner Award in Health & Wellness & Five Winning Strategies To Guide You
The venerable American Association for Advertising is welcoming the return of its prodigal son—the healthcare agency and its clients—by including a Health & Wellness category in its 2016 Partner Award. Marylyn Donahue reports
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology - Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
 Learn More
|
Marketing
Marketing Curative Therapies: Are We Ready?
In the past, critics claimed the industry could not develop a cure because it would “break the business health maintenance model.” However, as pharma stands on the precipice of a new era with a new definition of “cure” emerging, these critics may be right and wrong at the same time, writes Eric M. Bachman
...Read more |
Forecast
Pharma and Biotech Financial Forecast: Mostly Sunny
The pharma and biotech business is coming off a strong year but headwinds persist—a clear product strategy, focused around a more demanding customer base, is the best way to ensure smooth sailing in 2016. Peter Young reports
...Read more |
AmerisourceBergen
Patient-Centric Approach to Product Commercialization. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments. This requires aligning both R&D and marketing efforts with patient needs in order to drive positive outcomes— clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market. Click here for more information.
 Learn More
|
 |
 //Aclaris Therapeutics (Malvern, PA) announced that it has appointed Brett Fair as Senior Vice President of Commercial Operations.//Nuo Therapeutics (Gaithersburg, MD) has engaged Winter Harbor, LLC to assist the company in its financial restructuring process. In connection with the engagement, Shaun Martin, a principal at Winter Harbor, has been appointed Chief Restructuring Officer of Nuo.//Galena Biopharma (San Ramon, CA) announced the departure of the company's Chief Financial Officer, Ryan Dunlap, effective December 31, 2015. Mr. Dunlap was unable to relocate his family to the new company headquarters in San Ramon. The company has instituted a search for a new CFO.//Keryx Biopharmaceuticals (Boston, MA) appointed John P. Butler to its Board of Directors, pursuant to the company's financing transaction with The Baupost Group, LLC.//RedHill Biopharma (Tel-Aviv, Israel) appointed Rick D. Scruggs to its Board of Directors, effective January 1, 2016.//
|
|
|
|
|
